Patient Savings

Right for patients

Write for rosacea 

HELPING YOU SUPPORT YOUR ROSACEA PATIENTS

We’re here to guide you and your patients through our financial assistance program, designed to help support those in need throughout their rosacea journey. We’ve included the eligibility requirements below, so no matter your patients’ circumstances, you can help them start saving today

GALDERMA CARECONNECT CARD

Designed for patient access

Don’t allow cost to be a barrier to safe and effective treatment

Specifically designed for rosacea, ORACEA® (doxycycline, USP) 40 mg* Capsules are the only FDA-approved oral treatment for papulopustular rosacea1

They are also available as an authorized generic, to help make treatment more affordable for your patients

With the Galderma CAREConnect Card, the prescriptions you write are easily filled by pharmacies, and commercially insured patients may pay less out of pocket

image of orace capsules bottle and Galderma Care connect card

*30 mg immediate release and 10 mg delayed release beads
Galderma CAREConnect is only available for commercially insured or uninsured patients. Patients who are enrolled in a government-run or
government-sponsored healthcare plan with a pharmacy benefit are not eligible to use the Galderma CAREConnect Patient Savings Card 

AFFORDABLE TREATMENT

Help your rosacea patients start saving

Through Galderma CAREConnect, saving is remarkably easy. Simply direct your commercially insured patients to www.galdermacc.com, where they can download their very own Patient Savings Card and may pay as little as $0 on some Galderma prescription products

Patients pay

Commercially 
unrestricted

$0

Commercially
restricted or
cash pay

$60

careconnect

No activation is required, and the Patient Savings Card can be used at any participating pharmacy

Galderma CAREConnect is only available for commercially insured or uninsured patients. Patients who are enrolled in a government-run or government-sponsored healthcare plan with a pharmacy benefit are not eligible to use the Galderma CAREConnect Patient Savings Card
‘Commercially Unrestricted’ refers to a payment by a patient that has commercial coverage (excludes all government programs) through a pharmaceutical benefit plan and a specific product has no restrictions (PA, Step Edit, NDC block, HDHP) 

The authorized generic offers:

Same unique formulation

Same unique formulation

Same efficacy and safety

Same efficacy and safety

Bioequivalent alternative to help with cost

Bioequivalent alternative to help with cost

Same proven tolerability of ORACEA Capsules

Same proven tolerability of ORACEA Capsules

Confidence in the medication you prescribe

Confidence in the medication you prescribe

FAQS

Frequently Asked Questions

Sign up and

stay up-to-date

For the latest news, research, and insights into papulopustular rosacea, subscribe now! You’ll also receive patient resources and toolkits, helping you treat your patients throughout their rosacea journey

Important Safety Information

Indication: ORACEA® (doxycycline) 40 mg* capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA does not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in subjects treated with ORACEA were nasopharyngitis, diarrhea, hypertension and sinusitis. Warnings/Precautions: ORACEA should not be used to treat or prevent infections. ORACEA should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years) and may cause reversible inhibition of bone growth. If Clostridium difficile associated diarrhea (CDAD) occurs, may need to discontinue ORACEA. Although photosensitivity was not observed in clinical trials, ORACEA patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA treatment beyond 16 weeks and safety beyond 9 months have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

*30 mg immediate release and 10 mg delayed release beads

REFERENCES

1. ORACEA [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2014